Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Harpoon Therapeutics Inc.
Headquarters: South San Francisco, CA, United States of America
Website: N/A
Year Founded: 2015
Status: Acquired
BioCentury | Jan 28, 2025
Management Tracks
Thomas Barnes named CEO of Averna
Plus: Panetta given emeritus title at Biocom and updates from Kailera, Harness, Nuevocor, Janux, Umoja and more
BioCentury | Dec 14, 2024
Management Tracks
Gilead hires Dietmar Berger as CMO
Plus: Tanya Wallace to head of neuroscience and ophthalmology at AbbVie, and updates from Editas and Zentalis
BioCentury | Aug 14, 2024
Deals
Deals Report: Pair of Merck deals in APAC region; Recursion and Exscientia merging
Plus: Denmark-based Pharmacosmos buys G1, obtaining myelosuppression drug
BioCentury | Jan 13, 2024
Finance
JPM wrap: a BioCentury podcast
Takeouts, neuroscience innovation and investor sentiment to kick off 2024
BioCentury | Jan 12, 2024
Finance
The year of biotech’s recovery
Public Markets Preview: Investors say biotech outperformance in 2024 will hinge on the interest rate environment
BioCentury | Jan 8, 2024
Deals
Merck acquisition brings back hope for Harpoon’s trispecific technology
Merck will acquire Harpoon and its DLL3 trispecific for $680M
BioCentury | Jan 8, 2024
Deals
Ambrx turnaround culminates in $2B takeout by J&J
A fall 2022 reset positioned an ADC for prostate cancer as the biotech’s top priority under new leadership
BioCentury | Jan 3, 2024
Management Tracks
Rimac leaving Sagimet as CFO
Plus: Harpoon names new legal, HR officers, and updates from Alimera, Alaunos and Novo Holdings
BioCentury | Dec 15, 2023
Management Tracks
Amgen names Bradner CSO as Reese moves to CTO
Plus: Matthieu Coutet joins Sofinnova Partners, and updates from Vanqua Bio, Adela, Velia and more
BioCentury | Oct 23, 2023
Deals
Oct. 23 Quick Takes: Merck drops two Kelun ADCs
Plus: FDA guidance facilitates communication about off-label uses and updates from Verve, Celltrion, Sanofi, Regeneron, Revolution, Harpoon, Aligos
Items per page:
1 - 10 of 59